Open an account

Can Fite Biopharma

CANF · TEL

$1.78−$0.05 (−2.73%)TodayMarket closed ·
Prev close $1.83

About CANF

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company is headquartered in Petah Tikva, Central(Hamerkaz) and currently employs 5 full-time employees. The company went IPO on 2005-09-22. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Employees
5
Headquarters
Petah Tikva, Central(HaMerkaz)
Listed
Sep 22, 2005
Sector
Health Care
Industry
Biotechnology
Website
canfite.com

CANF key statistics

Market cap
18.39M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
30.21K
Volume
23.85K
Open price
$1.83
High today
$1.82
Low today
$1.77
52 Week high
$12.30
52 Week low
$1.75

Can Fite Biopharma (CANF) at a glance

As of Oct 23, 2026, Can Fite Biopharma (CANF) shares are priced at $1.78, giving the company a market cap of 18.39M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.77 and $1.82. The current price is 0.6% above the day's low and 1.9% below its high.

Volume so far is 23.85K shares, below the average of 30.21K shares a day.

Over the past year Can Fite Biopharma has ranged from $1.75 to $12.30, and now sits 0% of the way up that range.

Can Fite Biopharma met or beat analyst EPS estimates in 5 of the last 7 quarters. In Q4 FY23 it reported -$114.00 per share against an estimate of -$2,972.61.

The average analyst price target is $0.0504, 97.2% below the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $0.0504
Low
$0.0499
Now
$1.78
High
$0.0519

CANF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 7 quarters, by 150.2% on average.

  1. Q1 FY15: reported -$180.00 per share against an estimate of -$459.00
  2. Q2 FY15: reported -$930.00 per share against an estimate of -$275.40
  3. Q3 FY15: reported -$1,680.00 per share against an estimate of -$153.00
  4. Q4 FY15: reported $360.00 per share against an estimate of -$122.40
  5. Q2 FY23: reported $0.00 per share against an estimate of -$4,798.05
  6. Q3 FY23: reported $0.00 per share against an estimate of -$5,299.77
  7. Q4 FY23: reported -$114.00 per share against an estimate of -$2,972.61

CANF news

  • Vandana Singh

    Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

  • Vandana Singh

    Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients

  • Market-Moving News for July 1st

  • Akanksha Bakshi

    Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Market-Moving News for June 26th

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

Similar companies

Companies in the same industry as Can Fite Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.